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Abstract The aim of our study was to investigate whe-
ther genetic variants in the hypocretin receptor 1
(HCRTR1) gene could modify the occurrence and the
clinical features of migraine. Using a case–control strategy
we genotyped 384 migraine patients and 259 controls for
three SNPs in the HCRTR1 gene. Genotypic and allelic
frequencies of the rs2271933 non-synonymous polymor-
phism resulted different (v
2 = 9.872, p = 0.007;
v
2 = 8.108, p = 0.004) between migraineurs and controls.
The carriage of the A allele was associated with an
increased migraine risk (OR 1.42, 95% CI 1.11–1.81).
When we divided the migraine patients into different
subgroups, the difference reached the level of statistical
signiﬁcance only in migraine without aura. The different
genotypes had no signiﬁcant effect on the examined clin-
ical characteristics of the disease. In conclusion, our data
supports the hypothesis that the HCRTR1 gene could rep-
resent a genetic susceptibility factor for migraine without
aura and suggests that the hypocretin system may have a
role in the pathophysiology of migraine.
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Introduction
Migraine is a chronic neurovascular disease characterized
by recurrent headache attacks associated with autonomic,
gastrointestinal and focal neurological symptoms [1].
Migraine is a public health problem of great impact on both
the patient and society. The prevalence studies showed that
migraine affects 15–25% of women and 6–8% of men [2].
Migraine is rated as one of the most disabling chronic
disorders by the World Health Organization. The annual
cost of migraine-related loss in productivity is enormous
and it has been estimated to be the most costly neurological
disorder in Europe [3].
Migraine is a complex disorder that shows a strong (up
to 50%) genetic component with a probable multifactorial
inheritance [4]. Mutations in three genes encoding neural
ion channels, CACNA1A, ATP1A2, and SCN1A, have
been described in patients with familial hemiplegic
migraine (FHM), a rare monogenic, autosomal dominant
form of migraine with aura [5]. However, the success of
FHM, regarding discovery of genetic defects associated
with the disease, remains elusive in the common forms
of migraine, and causative genes have not been identiﬁed
yet [6].
Recently a new neurotransmitter system, the hypocretin
orexin system, has been implicated in neurological dis-
eases. This system consists of two neuropeptides trans-
mitters, hypocretin-1 and -2 (also termed orexin-A and -B),
that are encoded by a unique precursor, preprohypocretin,
and two G-protein coupled receptors (HCRTR1 and
HCRTR2), that act via PKC to phosphorilate voltage-
activated calcium channels [7, 8]. HCRTR1 has a pref-
erential afﬁnity for hypocretin-1, 50 times more than
hypocretin-2, while HCRTR2 has comparable afﬁnities
for the two peptides [9].
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located in the lateral hypothalamic area and in the posterior
hypothalamus [10]. The hypothalamic hypocretin neurons
may be divided into at least two different populations, a
lateral one playing a role in food intake and addiction [11]
and a more medial one involved, in particular, in stress and
arousal [12]. Hypocretin neurons project to wide targets, as
cerebral cortex, olfactory bulb, hippocampus, amygdala,
hypothalamus itself, midbrain, spinal cord, and brainstem;
in turn, they receive excitatory or inhibitory inputs from the
same areas [10]. Hypocretin systems are also involved in
circadian pathway, hormones secretion, and in emotional
and autonomic processes related to stress as well [13].
They are, therefore, crucial in the regulation of motiva-
tional and adaptative behavior to metabolic and environ-
mental stimuli.
Several functions regulated by hypocretins are signiﬁ-
cantly impaired in patients with migraine and this could be
relevant to the pathophysiology of the disease. In particu-
lar, premonitory symptoms preceding a migraine attack,
such as fatigue, yawning, excessive sleepiness and craving
for certain food, indicate an involvement of different
hypothalamic nuclei that might be related to the hypocretin
functions.
An alteration in orexin signaling makes an attractive
candidate to explain several of the symptoms observed in
patients with primary headaches. Our research group has
previously reported that the 1246G/A polymorphism of the
hypocretin receptor 2 (HCRTR2) gene is signiﬁcantly
associated with cluster headache [14]. This association was
conﬁrmed by a large study performed in Germany, show-
ing that homozygous carriers of the G allele had a twofold
increase in risk for the disease [15], but was not replicated
in a complex dataset of CH patients of Danish, Swedish,
and British origin [16]. Conversely, analyzing the same
polymorphism in migraine, no statistical difference was
found between cases and controls [17] and the same results
were obtained by an independent group [18]. Thereby, in
order to deepen the analysis of hypocretin system in
migraine pathogenesis, we hypothesized that HCRTR1
gene polymorphisms would modify the occurrence and the
clinical features of migraine patients. To test this hypoth-
esis, we performed a case–control association study in a
cohort of Italian migraine patients and in healthy controls.
Methods
Patients and controls
A total of 384 consecutive migraine patients (110 males,
274 females; mean age ± SD = 41.2 ± 13.2, mean age at
onset of disease ± SD = 18.5 ± 10.0 years), attending
the Headache Center of the University of Torino (Italy),
and the Psychiatric Clinic (St. Louis Hospital) of the
University of Torino, were involved in the case–control
association study. The diagnoses of Migraine without aura
(MO) (330 patients) and Migraine with aura (MA) (54
patients) were made according to the International Classi-
ﬁcation of Headache Disorders (IHCD-II) criteria [19]. A
standardized record of all the clinical and psychological
characteristics of migraine, suitable for computer analysis,
was obtained. A group of 259 sex, age and geographically
matched healthy subjects (81 males, 178 females, mean
age ± SD = 41.9 ± 12.9 years) were used as controls.
The controls were healthy blood donors and were screened
by a neurologist specialized in headaches in order to
exclude migraine or chronic tension-type headache. Writ-
ten informed consent was obtained from all participants
and the study was approved by the Hospital Ethics
Committee.
Genetic analysis
Genomic DNA was extracted using the QIAamp Mini Kit
(Qiagen S.p.A., Italy). We genotyped cases and controls for
three bi-allelic polymorphisms (SNP1 rs10914456, SNP2
rs4949449, and a non-synonymous SNP3 rs2271933
(I408 V) of the HCRTR1 gene, selected from SNPs data-
base of NCBI (http://www.ncbi.nlm.nih.gov/). These
polymorphisms have been shown to be polymorphic in
Western populations. PCR reactions were performed
according to standard conditions. Supplementary data are
available on request.
Statistics
v
2 test was used in verifying Hardy–Weinberg equilibrium.
Statistical analyses were performed using Genepop—
version 4.0 (http://wbiomed.curtin.edu.au/genepop), Sigma-
Stat—version 3.1 (Jandel Corp., 1994, San Rafael, CA,
USA), SVS 7 (http://www.goldenhelix.com) and SPSS
version 17. SNPs were assessed for both genotypic and
allelic association as well as the Armitage trend test.
ANOVA followed by Bonferroni correction for multiple
comparisons were used to compare the clinical character-
istics between cases and controls. Haploview program
version 4.1 (http://www.broad.mit.edu/mpg/haploview/)
was used for haplotype analysis and for pairwise linkage
disequilibrium, D0 and r
2. Genetic Power Calculation
(http://statgen.iop.kcl.ac.uk/gpc) was used to calculate the
power of the association study. According to the recent
guidelines for genetic association studies in neurological
disorders, the level of statistical signiﬁcance was taken at
p\0.01 [20], whereas for other comparisons the level of
signiﬁcance was taken at p\0.05.
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Association between HCRTR1 gene and migraine
Table 1 shows the genotype (GF) and the allele frequencies
(AF) of the three polymorphisms examined in the HCRTR1
gene (rs10914456, rs4949449, and rs2271933) and the
comparison between healthy controls and migraine
patients. Hardy–Weinberg equilibrium was veriﬁed for all
populations (data on request). No signiﬁcant differences
were found in the distribution of either genotypic or allelic
frequencies between cases and controls in HCRTR1
rs10914456 and rs4949449.
Conversely, analyzing the rs2271933 (1222G[A) non
synonymous polymorphism, a statistical difference was
found in the distribution of GF and AF between cases and
controls. The allelic frequency for 1222G was 0.69 in
controls and 0.61 in migraine patients, AF for 1222A was
0.31 in controls and 0.39 in migraineurs (v
2 = 8.108,
p = 0.004, power = 0.828). The carriage of the A allele
was associated with a signiﬁcantly increased disease risk
(OR 1.42, 95% CI 1.11–1.81). The distribution of geno-
typic frequencies between cases and controls resulted sig-
niﬁcantly different (v
2 = 9.872, p = 0.007, power =
0.819) as well. To assess the dosage effect of possessing
zero, one or two copies of the A-risk allele, according to an
additive model, the Armitage test for linear trend in pro-
portion was performed on the genotype frequency data.
However, the obtained p values were not signiﬁcant after
Bonferroni correction. When analyzing the dominant
model, the comparison between GA?AA vs. GG showed a
difference between cases and controls (v
2 = 9.217,
p = 0.002, power = 0.877), with an increased risk of
migraine in GA?AA carriers compared with GG carriers
(OR = 1.66; 95% CI = 1.19\OR\2.32), according to
a dominant model (Table 2). The permutation test of one
million times generated a total v
2 of 8.518 (p = 0.0057) in
order to observe a signiﬁcant difference in rs2271933
analysis. When analyzing the gender effect, the association
according to the dominant model was conﬁrmed only in
female patients (p = 0.003, OR = 1.80; 95% CI =
1.22\OR\2.65) and not in males, probably due to the
low-number of this subgroup. The present study had a
power of 0.82 to detect a signiﬁcant association, assuming
a prevalence of migraine = 0.12, a high-risk allele fre-
quency = 0.3, a genotypic relative-risk GA = 1.5, and a
genotypic-risk relative-risk AA = 2.
When we divided the migraine patients into two dif-
ferent subgroups (migraine with aura—MA—and migraine
without aura—MO), according to IHCD-II criteria, the
difference reached the level of statistical signiﬁcance only
in MO subgroup. The different genotypes had no signiﬁ-
cant effect on the examined migraine clinical features
(nausea, vomiting, phono and photophobia, pulsating pain,
unilateral pain, age at onset of the disease, and duration of
the disease and frequency of migraine attacks) (Table 3).
Haplotype block structure analysis of HCRTR1 gene
Multilocus haplotypes are usually more informative than
any single marker, so we performed a haplotype analysis of
HCRTR1 gene. Pairwise analysis showed that the HCRTR1
SNPs are in high LD: D0 more than 0.91, r
2 more than 0.7
and LOD more than 55 and was found for the three nearby
SNPs. In our Italian population, the latter results evidenced
a strong LD in the HCRTR1 region, according to other
studies [19], suggesting that HCRTR1 gene is located on
Table 1 Genotype and Allele Frequencies of the HCRTR1 polymorphisms in migraine patients and controls
GF AF
HCRTR1 SNP1 rs10914456 C/C (%) C/T (%) T/T (%) C (%) T (%)
Controls 108 (41.7) 122 (47.1) 29 (11.2) 338 (65.3) 180 (34.7)
Migraine patients 146 (38.1) 188 (49.0) 50 (13.0) 480 (62.5) 288 (37.5)
HCRTR1 SNP2 rs4949449 G/G (%) G/T (%) T/T (%) G (%) T (%)
Controls 104 (40.2) 129 (49.8) 26 (10.0) 337 (60.6) 181 (39.4)
Migraine patients 147 (38.3) 190 (49.5) 47 (12.2) 484 (63.0) 284 (37.0)
HCRTR1 SNP3 rs2271933 G/G (%) G/A (%) A/A (%) G (%) A (%)
Controls 125 (53.3) 108 (41.7)
a 26 (10.0)
a 358 (69.1) 160 (30.9)
b
Migraine patients 138 (36.0) 194 (50.5) 52 (13.5) 470 (61.2) 298 (38.8)
p values were calculated by the v
2 test from 392 (genotype) or 292 (allele) contingency tables
GF genotypic frequency, AF allelic frequency
a GF v
2 = 9.872, p = 0.007, power = 0.819
b AF v
2 = 8.108, p = 0.004, power = 0.828
J Headache Pain (2011) 12:193–199 195
123the same LD block. For the HCRTR1 gene, the analysis
identiﬁed a total of eight different haplotypes, but only four
exceed 1% value (Table 4). The TTG and TTA haplotypes
resulted signiﬁcantly different in cases and controls
(v
2 = 25.537, p\0.0001; v
2 = 6.151, p = 0.013). The
permutation test (one million times) generated identical
values. The carriage of the TTA haplotype was associated
with a signiﬁcantly increased disease-risk (OR 1.37, 95%
CI 1.07–1.74) (Table 2). The latter data conﬁrms the dif-
ferences between cases and controls, underlining in par-
ticular the rs2271933 G[A role.
Discussion
The present study of an Italian population provides evi-
dence of a genetic association between a non-synonymous
polymorphism (G1222A) in exon 7 of HCRTR1 gene and
migraine. Subject carriers for A allele showed an increased
disease risk in comparison with G carriers. Patients with
the AA genotype showed an approximately twofold
increased risk for migraine compared with carriers of the
GG genotype, while subjects with GA genotype had a
modest, but signiﬁcant 1.42-fold risk of developing the
disease compared with homozygotes for the G allele.
Haplotype analysis conﬁrmed the association. When the
patients were divided into different clinical subgroups
(migraine with and without aura), the signiﬁcant difference
Table 2 Genotypic, allelic, and
haplotypic comparisons in
HCRTR1 gene I408V
polymorphism between
migraine patients and controls
HCRTR1 SNP3 I408V (rs2271933) Chi p OR 95% CI
Alleles
A vs. G v
2 = 8.108 p = 0.004 1.42 1.11\OR\1.81
Genotypes
AA vs. GG v
2 = 4.355 p = 0.037 1.81 1.03\OR\3.19
GA vs. GG v
2 = 7.556 p = 0.006 1.42 1.11\OR\1.81
AA vs. GA v
2 = 0.071 p = 0.789 1.11 0.64\OR\1.95
GA?AA vs. GG (dominant model) v
2 = 9.217 p = 0.002 1.66 1.19\OR\2.32
AA vs. GG ? GA (recessive model) v
2 = 1.467 p = 0.226 1.40 0.83\OR\2.30
Haplotypes
TTA v
2 = 6.151 p = 0.013 1.37 1.07\OR\1.74
TTG v
2 = 25.537 p =\0.001 0.10 0.03\OR\0.30
Table 3 Clinical characteristics
of migraine patients according
to HCRTR1 I408V different
genotypes
G/G G/A A/A p value
Number 138 194 52
Age at onset of the disease ± SD (years) 23.22 ± 14.08 21.10 ± 11.67 23.04 ± 12.32 p = 0.278
Duration of the disease ± SD (years) 19.93 ± 13.60 22.69 ± 13.37 21.39 ± 12.85 p = 0.181
Frequency of migraine attacks (attacks for
year)
51.00 ± 61.69 47.08 ± 57.44 41.11 ± 62.64 p = 0.584
Nausea 97 142 39 p = 0.847
Vomiting 54 83 14 p = 0.292
Phono or photophobia 110 164 45 p = 0.514
Unilateral pain 31 131 82 p = 0.055
Pulsating pain 96 142 40 p = 0.639
Table 4 Haplotypes of the HCRTR1 polymorphisms in migraine
patients and controls
Controls Migraineurs
N (%) N (%)
Haplotype
CGG 325 0.628 450 0.586
TTA 149 0.287 273* 0.356
TTG 26** 0.051 4 0.005
CGA 7 0.012 20 0.025
CTG 4 0.008 5 0.007
TGA 3 0.006 3 0.004
TGG 2 0.004 10 0.013
CTA 2 0.004 3 0.004
518 768
* p = 0.01
** p =\0.001
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migraineurs without aura. Finally, the different HCRTR1
G1222A genotypes did not seem to modify the main
clinical features of the disease.
To the best of our knowledge, this is the ﬁrst study
evaluating the association between migraine and the
HCRTR1 gene and additional studies are needed to conﬁrm
our ﬁndings. Genetic association studies are exposed to
several biases, including phenotypic deﬁnition of the dis-
ease,adequatesamplesizeofpatientsandcontrols,selection
of the polymorphisms, and population stratiﬁcation. How-
ever, our study had a power of 0.82 to detect a signiﬁcant
association, even if the possibility of undetected bias cannot
be excluded. In our study, we found a signiﬁcant association
exclusivelyinfemalepatients. However,thepowertodetect
a signiﬁcant association in males was low and these results
need to be interpreted with caution. In animal studies,
HCRTR1 expression was signiﬁcantly higher in female
hypothalamus with respect to males [20], showing a sexual
dimorphismintheexpressionofhypocretinreceptors.When
we divided the migraine patients into different subgroups,
the difference reached the level of statistical signiﬁcance
only in migraine without aura subgroup. In literature, MO
and MA are extensively discussed to be deﬁned as different
diseaseentities[21]withadifferentgeneticbackground,and
our results could further support this view.
The G[A polymorphism of the HCRTR1 gene leads to
an aminoacid substitution of isoleucine at position 408 by
valine, which could engender an altered receptor function.
Ile408Val mutation is located in the cytoplasmatic tail. It is,
therefore, a potential binding site for G proteins, and could
alter intracellular signal transduction. However, it is unclear
whether this variation may change the function of the pro-
tein, modifying its afﬁnity for ligands, its coupling to
effectors, its dimerization, or its formation of heterodimers
(e.g., with cannabinoid CB1 receptors [22]). This genetic
variant was reported to be a benign polymorphism in human
narcolepsy [23]. Additionally, an association between the
aforementioned polymorphism in polydipsic-hyponatremic
schizophrenic patients when compared with non-polydipsic
patients was observed, but the study failed to detect a dif-
ference in intracellular calcium in mutant cell lines [21].
Etiopathogenetic mechanisms underlying migraine are
poorly understood [21]. Many migraineurs experience
premonitory autonomic and endocrine symptoms preceding
the onset of a migraine attack that may indicate a primary
hypothalamic dysfunction [24]. A recent paper highlighted
the importance of hypothalamus in migraine pathophysio-
logy [25]. This hypothesis is also supported by an
experimental study that demonstrated the existence of a
hypothalamic activation in migraine attacks [26] with the
positron emission tomography (PET). The interrelation
between hypothalamus and interconnected brainstem area
could play a key role in migraine physiopathology. In the
hypothalamus, HCRTR1 mRNA is densely expressed in
the anterior and posterolateral hypothalamus. Outside the
hypothalamus, HCRTR1 mRNA are detected in the dorsal
raphe nucleus, thalamus, rhombencephalon, periaqueductal
gray, hippocampus, spinal cord and dorsal root ganglia and
most prominently, in the noradrenergic neurons of the
locus coeruleus [27]. The importance of hypocretinergic
projections is stressed by their inﬂuence on a wide range of
many physiological and behavioral processes like as food-
intake, pain modulation, sleep-wake cycle and vigilance,
reward processing, stress responses, and regulation of
autonomic system [13, 28].
Experimental data suggest that the posterior hypothala-
mus is involved in the modulation of nociceptive pro-
cessing in humans [29]. The hypothalamic hypocretinergic
system projects of many areas involved in pain processing
within the CNS and the hypocretins have been suggested to
play a role in pain pathway. Stimulation of nociceptive
trigeminovascular afferents leads to activation of neurons
in the posterior hypothalamus [30]. An intrathecal admin-
istration of hypocretin-1 produces analgesic effects in
experimental animals [31] and injection of orexin-A
reduced mechanical allodynia in a neuropathic pain model
[32]. In addition, the administration of a selective non-
peptide Hcrt-1 antagonist (SB-334867) reversed the hypo-
cretin-1 analgesic effects, suggesting the presence of a
descending orexinergic inhibitory system [33]. Finally,
after hypocretin microinjection into the posterior hypo-
thalamus, hypocretin-1 decreased the A- and C-ﬁber
responses to dural and electrical stimulation: this suggests a
link between the hypocretinergic system and autonomic
changes as well as nociceptive phenomena observed in
primary headache disorders [34].
Intriguingly, the recent ﬁndings suggested an exciting
role for hypocretins in drug addition and reward-seeking.
Orexin neurons are stimulated by contextual stimuli asso-
ciated with cocaine, morphine, ethanol, or food reward
[35], indicating that the orexin system may be involved in
drug-seeking triggered by associative contexts. Addition-
ally, drug reward, reinstatement of drug seeking and psy-
chomotor sensitization appear to be mediated primarily by
HCRTR1, and the blockade of orexin signaling at
HCRTR1, via the selective antagonist SB-334867 (SB), has
been shown to attenuate cue- and stress-induced rein-
statement of cocaine- and ethanol-seeking [36]. About
3–4% of the general population worldwide suffer from
chronic daily headache associated with the overuse of
headache symptomatic medication making it a signiﬁcant
social problem. A recent research showed signiﬁcantly
higher concentrations of hypocretin-1 in patients with
medication overuse headache and in patients with chronic
migraine, evidencing a signiﬁcant correlation with monthly
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role of hypocretinergic system in motivational state and
addictive behaviors to drugs of abuse.
Interestingly, narcoleptic patients exhibit a high-degree
of comorbidity with migraine. Narcoleptic patients have
low or undetectable hypocretin-1 levels in cerebrospinal
ﬂuid (CSF) as well, and show 85–95% reduction in the
number of hypocretin neurons in the hypothalamus [38].
Mutations in HCRTR2 that is abundantly expressed in
regions highly important for the maintenance of arousal
result in narcoleptic symptoms in mice and dogs [39, 40].
Alterations in hypocretin neurotransmission have been
found in additional sleep disorders, such as secondary
hypersomnia and periodic hypersomnia [41, 42]. At pres-
ent, new drugs, such as SB649868 and ACT- 078573,
which are selective antagonists of hypocretin receptors, are
under development for the treatment of neurological dis-
orders. With these exciting premises, the study of the
effects of these drugs in patients with primary headaches
will provide data of particular interest.
An alternative explanation of our observed data might be
related to the linkage disequilibrium with other disease
genetic variants in nearby genes, which are responsible for
thisassociation.Thegeneticcase–controlsassociationstudy
forcomplexdisordershastheadvantageofbeingpowerfulto
detect loci of small effect size and relatively high-allele
frequencies inthe population, butit islesssensitivetodetect
and deﬁne loci beyond a narrow distance surrounding the
markers compared with linkage studies. At present, genome
wide scan studies have identiﬁed several loci for migraine
susceptibility [23], but none in the 1p33. This chromosomal
region could deserve further investigation.
In conclusion, our data supports the hypothesis that the
HCRTR1 gene could represent a genetic susceptibility
factor for migraine without aura and that the hypocretin
neuronal system may have a role in the pathophysiology of
migraine. Additional studies in different population are
warranted to conﬁrm and pinpoint our ﬁndings.
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